RT Journal Article
SR Electronic
A1 Kuznar, Wayne
T1 DECIDE
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 9
SP 19
OP 19
DO 10.1177/1559897715588476
UL http://mdc.sagepub.com/content/15/9/19.abstract
AB The DECIDE study demonstrates that the humanized monoclonal antibody daclizumab high-yield process is superior to interferon beta-1a on brain magnetic resonance imaging measures of disease activity in patients with relapsing-remitting multiple sclerosis, supporting previous findings of a reduction in the annualized relapse rate.